



Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Format:

Abstract ▾

Send to ▾

Mol Oral Microbiol. 2017 Feb;32(1):74-88. doi: 10.1111/omi.12155. Epub 2016 Apr 5.

A bacterial-biofilm-induced oral osteolytic infection can be successfully treated by immuno-targeting an extracellular nucleoid-associated protein.

Freire MO^{1,2}, Devaraj A³, Young A⁴, Navarro JB³, Downey JS⁴, Chen C⁴, Bakaletz LO³, Zadeh HH^{4,5}, Goodman SD³.

Author information

- 1 Department of Applied Oral Sciences, The Forsyth Institute, Cambridge, MA, USA.
- 2 Department of Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
- 3 Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, and The Ohio State University College of Medicine, Columbus, OH, USA.
- 4 Division of Periodontology, Diagnostic Sciences & Dental Hygiene Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
- 5 Laboratory for Immunoregulation and Tissue Engineering (LITE), University of Southern California, Los Angeles, CA, USA.

Abstract

Periodontal disease exemplifies a chronic and recurrent infection with a necessary biofilm component. Mucosal inflammation is a hallmark response of the host seen in chronic diseases, such as colitis, gingivitis, and periodontitis (and the related disorder peri-implantitis). We have taken advantage of our recently developed rat model of human peri-implantitis that recapitulates osteolysis, the requirement of biofilm formation, and the perpetuation of the bona fide disease state, to test a new therapeutic modality with two novel components. First we used hyperimmune antiserum directed against the DNABII family of proteins, now known to be a critical component of the extracellular matrix of bacterial biofilms. Second we delivered the antiserum as cargo in biodegradable microspheres to the site of the biofilm infection. We demonstrated that delivery of a single dose of anti-DNABII in poly(lactic-co-glycolic acid) (PLGA) microspheres induced significant resolution of experimental peri-implantitis, including marked reduction of inflammation. These data support the continued development of a DNABII protein-targeted therapeutic for peri-implantitis and other chronic inflammatory pathologies of the oral cavity in animals and humans.

KEYWORDS: *Aggregatibacter actinomycetemcomitans* ; DNABII protein; biofilm; inflammation; integration host factor

Full text links



Save items

 Add to Favorites ▾

Similar articles

Development of an animal model for *A* [J Periodontol. 2011]

Review Comparative biology of chronic [Periodontol 2000. 2010]

Integration of non-oral bacteria into in vitro oral [Virulence. 2015]

Frequency of periodontal pathogens [Arch Oral Biol. 2013]

Review Microbiological diversity of peri [Adv Exp Med Biol. 2015]

[See reviews...](#)

[See all...](#)

Cited by 4 PubMed Central articles

Review Targeting microbial biofilm: [Nat Rev Microbiol. 2017]

A Human Biofilm-Disrupting (microb Agents Chemother. 2...]

Nontypeable *<i>Haemophilus* Proc Natl Acad Sci U S A. 2017]

[See all...](#)

Related information